HIV Health and Wellness

US: Administration Proposes Rule To Reverse Protections For Transgender Patients

The federal Department of Health and Human Services is proposing to roll back an Obama-era policy intended to protect transgender people from discrimination in health care.

Polish towns go 'LGBT free' ahead of bitter European election campaign

Teresa Drzewiecka grew up during World War Two, when German and Soviet troops battled for control of her town of Swidnik in eastern Poland. Now 83, she sees another threat to her country’s survival: lesbian, gay, bisexual and transgender (LGBT) people.

US: Gilead CEO insists federal government patent for HIV prevention pill Truvada is invalid

The chief executive of Gilead Sciences, the nation’s leading manufacturer of HIV drugs, defended the high cost of a key drug that prevents the lethal infection, telling a House committee Thursday that its hefty profits pay for continued research.

US: Gilead is accused of cutting anti-competitive deals to extend profit on HIV drug combinations

Combination drug “cocktails” to treat HIV infection are an important part of patients’ routine, allowing them to reduce the number of pills they must take each day. But the lifesaving tablets also were the focus of anti-competitive schemes by the nation’s leading HIV drug manufacturer, Gilead Sciences, according to a consumer lawsuit filed Tuesday.

China: Transgender people risk their lives with dangerous self-surgery

Transgender people in China are performing highly dangerous surgery on themselves and buying unsafe hormone treatments on the black market because it is almost impossible for them to access the health care they urgently need, Amnesty International said in a new report

US: Official Statement Responding to Gilead Sciences’ Announcement on a Generic Version of Truvada

Even their announcement today leaves Gilead with exclusive rights to Truvada as PrEP for another 15 months and Teva as the only generic manufacturer on the U.S. market. This will do little to reduce the price in a way that will increase access and PrEP4All remains suspicious of the terms and lack of transparency surrounding the Teva settlement.